Evidence map›Paper›PMID 33052352›Full record

ArticlemedRxiv : the preprint server for health sciences2020

SARS-CoV-2 genomic characterization and clinical manifestation of the COVID-19 outbreak in Uruguay.

Victoria Elizondo, Gordon W Harkins, Batsirai Mabvakure, Sabine Smidt, Paul Zappile, Christian Marier, Matthew Maurano, Victoria Perez, Natalia Mazza, Carolina Beloso and 15 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 4 countries.

Victoria ElizondoLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Gordon W HarkinsSouth African Medical Research Council Capacity Development Unit, South African National Bioinformatics Institute, University of the Western Cape, Bellville, South Africa.
Batsirai MabvakureDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.
Sabine SmidtSouth African Medical Research Council Capacity Development Unit, South African National Bioinformatics Institute, University of the Western Cape, Bellville, South Africa.
Paul ZappileGenome Technology Center, Office for Science and Research, NYU Langone Health, New York, New York, United States of America.
Christian MarierGenome Technology Center, Office for Science and Research, NYU Langone Health, New York, New York, United States of America.
Matthew MauranoDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, United States of America.
Victoria PerezLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Natalia MazzaLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Carolina BelosoLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Silvana IfranLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Mariana FernandezLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Andrea SantiniLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Veronica PerezLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Veronica EstevezLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Matilde NinLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Gonzalo ManriqueLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Leticia PerezLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Fabiana RossLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Susana BoschiLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Maria Noel ZubillagaLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Raquel BallesteLaboratorio de Biología Molecular, Asociación Española Primera en Salud, Montevideo, Uruguay.
Simon DellicourSpatial Epidemiology Lab. (SpELL), Université Libre de Bruxelles, Bruxelles, Belgium.
Adriana HeguyGenome Technology Center, Office for Science and Research, NYU Langone Health, New York, New York, United States of America.
Ralf DuerrDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, United States of America.
Office of Science · USNew York University · USSouth African Medical Research Council · ZAInstituto de Investigaciones Biológicas Clemente Estable · UYJohns Hopkins University · USUniversité Libre de Bruxelles · BE

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1M
Novel HIV-1 Env trimer probes for efficient isolation of broadly neutralizing antibodiesR01AI122953 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WU, XUELING · 2016 to 2019
$2.6M
NCI NIH HHS P30 CA016087NIAID NIH HHS R01 AI122953
6 · The paper itself

Abstract

COVID-19 is a respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and declared by the World Health Organization a global public health emergency. Among the severe outbreaks across South America, Uruguay has become known for curtailing SARS-CoV-2 exceptionally well. To understand the SARS-CoV-2 introductions, local transmissions, and associations with genomic and clinical parameters in Uruguay, we sequenced the viral genomes of 44 outpatients and inpatients in a private healthcare system in its capital, Montevideo, from March to May 2020. We performed a phylogeographic analysis using sequences from our cohort and other studies that indicate a minimum of 23 independent introductions into Uruguay, resulting in five major transmission clusters. Our data suggest that most introductions resulting in chains of transmission originate from other South American countries, with the earliest seeding of the virus in late February 2020, weeks before the borders were closed to all non-citizens and a partial lockdown implemented. Genetic analyses suggest a dominance of S and G clades (G, GH, GR) that make up >90% of the viral strains in our study. In our cohort, lethal outcome of SARS-CoV-2 infection significantly correlated with arterial hypertension, kidney failure, and ICU admission (FDR < 0.01), but not with any mutation in a structural or non-structural protein, such as the spike D614G mutation. Our study contributes genetic, phylodynamic, and clinical correlation data about the exceptionally well-curbed SARS-CoV-2 outbreak in Uruguay, which furthers the understanding of disease patterns and regional aspects of the pandemic in Latin America.

Identifiers

PMID33052352
PMCPMC7553156
OpenAlexW3092258615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.